Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 206-019-2 | CAS number: 288-32-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
In vitro
Imidazole was tested in the standard Ames test and in the preincubation Ames test conducted under GLP and according to the OECD TG 471. The substance was tested with Salmonella typhimurium TA 1535, TA 100, TA 1537, and TA 98 both in the presence and absence of metabolic activation in concentrations up to 5000 μg/plate. No mutagenic or bacteriotoxic effect was noted (BASF SE, 1992). According to OECD TG 471, an additional strain of either E. coli WP2 uvrA, or E. coli WP2 uvrA (pKM101), or S. typhimurium TA102 needs to be investigated. In a second Ames test, the S. typhimurium strain TA102 was investigated. In this study by Forster et al. (1992), imidazole and its metabolites hydantoin, hydantoic acid, and N-acetyl-imidazole were also negative in a standard-plate Ames-test equivalent to the OECD TG 471 with S. typhimurium TA 97, TA 98, TA 100, and TA 102 in the presence and absence of metabolic activation. Test substance concentrations were up to and including 10,000 μg/plate without reaching cytotoxicity. In a third Ames test, Salmonella typhimurium strains TA1535, TA1537, TA1538, TA98 and TA100 were exposed to concentrations of 0, 62.5, 125, 250, 500, and 1000 µg/plate were tested in triplicate, in the presence and absence of S9 -mix (BASF SE, 1979). The number of revertant colonies in all cases was less than twice the corresponding solvent control values, when tested up to the maximum level of 1000 µg/plate. Imidazole and its metabolites showed no mutagenicity in bacterial in-vitro test systems in the presence or absence of metabolic activation.
In the same study by Forster et al. (1992) it was determined that imidazole did not induce Unscheduled DNA Synthesis (UDS) in rat primary hepatocytes. The test method used was equivalent to the OECD TG 482. The test substance concentrations (0.25, 0.5, 1, 2, 4 mg/mL) reached the cytotoxic concentration range. Cell survival was 50% at 1 mg/mL (Forster et al., 1992). However, a negative UDS is not sufficient information to conclude on the induction of gene mutation by a substance.
Besides this UDS to investigate the potential mutagenicity of the test substance, a mammalian gene mutation test according to OECD 476 and GLP in V79 Chinese hamster cells (HPRT locus) was conducted with imidazole (Harlan, 2010). The assay was performed in two independent experiments, using two parallel cultures each. The first main experiment was performed with and without liver microsomal activation and a treatment period of 4 hours. The second experiment was performed with a treatment time of 4 hours with and 24 hours without metabolic activation. The maximum concentration was 700.0 µg/mL, corresponding to a molar concentration of about 10 mM of the test item. 7,12-dimethylbenz(a)anthracene (DMBA) and Ethylmethane sulfonate (EMS) were used as positive controls in experiment with and without metabolic activation, respectively. Positive as well as negative controls gave expected results.
The induction factor exceeded the threshold of three times the corresponding solvent control in the first culture of experiment I with metabolic activation at 700 µg/mL and in the second culture without metabolic activation at 43.8 and 350 µg/mL. The increase observed in the second culture without metabolic activation was not dose dependent as indicated by the lacking statistical significance and not reproduced in the parallel culture under identical conditions. Although there was a statistically significant increase of the mutation frequency in the presence of metabolic activation, the effect was not reproducible in the parallel culture or in both cultures of the second experiment with metabolic activation.
No other relevant and reproducible increase in mutant colony numbers/10E6 cells was observed in the main experiments up to the maximal concentration. Therefore, Imidazole was considered to be non-mutagenic in this HPRT assay.
In order to confirm the assessment of the HPRT assay, a new guideline conforming mouse lymphoma
assay was performed as this test system is considered more sensitive than the HPRT assay. The test substance was tested for its ability to induce gene mutations at the thymidine kinase (TK) locus in L5178Y TK+/- mouse lymphoma cells in vitro with the microwell method (BASF SE 2015). Two independent experiments were carried out with and without the addition of liver S9-mix from phenobarbital- and β-naphthoflavone induced rats (exogenous metabolic activation). An initial range-finding cytotoxicity test for the determination of the experimental doses was performed. The first experiment was conducted with and without S9-mix (4-hour exposure period) with concentrations of 0, 87.5, 175.0, 350.0, and 700.0 μg/mL test substance. The second experiment was conducted without S9-mix (24 -hour exposure period) with concentrations of 0, 87.5, 175.0, 350.0, and 700.0 μg/mL test substance and with S9-mix (4 -hour exposure period) and test substance concentrations of 0, 100.0, 200.0, 400.0, and 700.0 μg/mL. Subsequently, cells were cultured for an expression period of about 48 hours and then cultured in selection medium for another approx. 10 days. Finally, the number of large and small colonies was determined. The negative controls gave mutant frequencies within the range expected for the L5178Y TK+/- mouse lymphoma cell line. Both positive controls, methyl methansulfonate and cyclophosphamide, led to the expected increase in the frequencies of forward mutations. No cytotoxicity indicated by either reduced relative cloning efficiency or reduced relative total growth of below 20% of control was observed in both experiments. Based on the results of the present study, the test substance did not cause any biologically relevant increase in the mutant frequencies either without S9-mix and/or after adding a metabolizing system in two experiments performed independently of each other. Thus, under the experimental conditions described, the test substance did not induce forward mutations in vitro in the mouse lymphoma assay with L5178Y TK+/- cells in the absence and the presence of metabolic activation.
In vivo
Imidazole hydrochloride was tested in a micronucleus test in accordance with the OECD TG 474 under GLP conditions in mice, dosed once by gavage with 500, 1000, and 2000 mg/kg bw/d. The salt imidazole hydrochloride dissociates into protonated imidazole and chloride in the stomach following oral gavage and did not induce micronuclei at any dose or any harvesting time, which were set at 16, 24, and 48 hrs after dosing. The animals showed signs of toxicity at 500 mg/kg bw and above. The number of polychromatic and normochromatic erythrocytes was not statistical significantly different from the control, therefore it may be concluded, that imidazole was not toxic to the bone marrow. However, imidazole was detected in the plasma of Wistar rats dosed orally (gavage) with approximately 17 mg/kg bw of imidazole, indicating imidazole is absorbed (Pagella et al 1983). This suggests that the bone marrow will have been exposed in this micronucles test. Imidazol was found to be not clastogenic or aneugenic in this test (BASF SE, 1993).
Short description of key information:
No mutagenicity was observed in the Ames tests performed. No clastogenic or aneugenic effects were found in the in vivo mouse micronucleus test. No unscheduled DNA synthesis was induced in primary rat hepatocytes, and no mutagenicity was observed in the HPRT gene of V79 Chinese hamster cells and in a mouse lymphoma assay in the absence and presence of metabolic activation. Based on all available data it can be concluded that imidazole is not genotoxic.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.